

PHM037B – Table of Contents

MAY 2008	I
INTRODUCTION	XLIV
STUDY GOALS AND OBJECTIVES	XLIV
REASONS FOR DOING THE STUDY	XLIV
AUDIENCE FOR THE REPORT	XLV
SCOPE AND FORMAT	XLV
METHODOLOGY AND INFORMATION SOURCES	XLV
BCC INFORMATION AND RELATED BCC STUDIES	XLVI
AUTHOR’S CREDENTIALS	XLVI
BCC ONLINE SERVICES	XLVII
DISCLAIMER	XLVII
SUMMARY	XLVIII
AGING POPULATIONS AND CHRONIC DISEASES	XLVIII
OVERALL GLOBAL PHARMACEUTICAL MARKETS	L
SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 (\$ BILLIONS)	LI
SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, 2006-2013 (\$ BILLIONS)	LI
OVERVIEW	1
BACKGROUND ON THE INDUSTRY	1
RECENT HISTORY	1
BENEFITS, PROBLEMS, AND REGULATION	1
CHANGES IN THE INDUSTRY	2
HEALTHCARE EXPENDITURES	3
TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)	4
THE PHARMACEUTICAL INDUSTRY	5
TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 (\$ BILLIONS)	5
RESEARCH AND DEVELOPMENT EXPENDITURES	5
TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 (\$ BILLIONS)	6
SECTOR PERFORMANCE	6
BRANDED PHARMACEUTICALS	6
TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	7
TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	7
TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	8
TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	8
UNITED STATES	9

INTRODUCTION	9
TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	9
POPULATION AND DEMOGRAPHICS	9
TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)	10
FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)	10
TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)	11
THE U.S. HEALTHCARE SYSTEM	11
HEALTHCARE EXPENDITURES IN THE U.S.	11
FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 (\$ BILLIONS)	12
TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006	13
TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 (\$ BILLIONS, %)	14
TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 (\$ BILLIONS)	15
COMMON HEALTH PROBLEMS IN THE U.S.	15
TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)	15
ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS	16
OBESITY AND RELATED CONDITIONS	16
DIABETES	17
CARDIOVASCULAR DISEASE	18
TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)	18
SMOKING	19
CANCER	19
TABLE 16 INVASIVE CANCER, U.S., 2004 (%)	19
TABLE 16 (CONTINUED)	20
TABLE 17 CANCER DEATHS, U.S., 2004 (%)	20
TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)	21
HIV INFECTION	21
GOVERNMENT REGULATIONS	22
INTRODUCTION	22
DRUG DISCOVERY	23
Preclinical Testing and Submission of an IND	24
CLINICAL TRIALS	25
TIMELINE AND COSTS	26
SUBMISSION OF AN NDA OR BLA	26
POST-FDA APPROVAL	27
NEW DRUG APPROVALS	28
FIGURE 3 NME APPROVALS, 1997-2007	28
FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007	29
TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007	30
DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?	31
BLOCKBUSTER DRUGS	32

TABLE 20 NME APPROVALS BY DISORDER, 2004–MARCH 20, 2008	33
OTHER SUCCESSFUL THERAPEUTIC AGENTS	34
TABLE 21 BOTOX SALES, 1993-2012 (\$ MILLIONS)	34
IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY?	35
PHARMACEUTICAL PRICING	36
FACTORS AFFECTING DRUG PRICES	36
PHARMACY BENEFIT MANAGERS (PBMS)	37
TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)	38
Pharmacy Benefit Managers ... (Continued)	39
PHARMACEUTICAL FLOW FROM MANUFACTURER TO PATIENT	40
PHARMACEUTICAL WHOLESALING	40
TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (% , \$ BILLIONS)	41
PHARMACEUTICAL RETAILING	41
TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)	41
EXPORT–IMPORT PROFILE	42
TABLE 25 EXPORT–IMPORT PROFILE, U.S., 1995–2006 (\$ BILLIONS)	42
MARKET SECTORS	43
BRANDED PRESCRIPTION PHARMACEUTICALS	43
TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	43
TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 (\$ BILLIONS)	44
GENERIC DRUGS	44
TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	45
OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.S.	45
TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	46
IMPORTANT ORGANIZATIONS IN THE U.S.	46
PHARMA, THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	46
GPHA, GENERIC PHARMACEUTICAL ASSOCIATION	46
CHPA (CONSUMER HEALTHCARE PRODUCTS ASSOCIATION)	47
COMPANY PROFILES: UNITED STATES	47
ABBOTT LABORATORIES	47
BIOGEN IDEC	48
AMGEN	49
BRISTOL-MYERS SQUIBB	50
FOREST LABORATORIES	51
GENENTECH	51
GENZYME	52
JOHNSON & JOHNSON	53
ELI LILLY AND COMPANY	54
MERCK & CO. INC.	55

PFIZER	56
WYETH PHARMACEUTICALS	57
TEVA PHARMACEUTICALS	57
Teva North America	58
CANADA	59
INTRODUCTION	59
TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	59
POPULATION AND DEMOGRAPHICS	59
TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)	60
FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)	60
TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)	61
THE CANADIAN HEALTHCARE SYSTEM	61
HEALTHCARE EXPENDITURE IN CANADA	62
TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005	62
COMMON HEALTH PROBLEMS IN CANADA	62
ALZHEIMER'S DISEASE AND RELATED DEMENTIAS	62
OBESITY AND RELATED CONDITIONS	63
DIABETES	63
CARDIOVASCULAR DISEASE AND CANCER	63
HIV INFECTION	64
PHARMACEUTICAL PRICING	64
MARKET SECTORS	65
BRANDED PRESCRIPTION PHARMACEUTICALS	65
TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	65
GENERIC DRUGS	65
TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	66
OVER-THE-COUNTER (OTC) MEDICATIONS IN CANADA	67
TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	67
TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)	67
IMPORTANT ORGANIZATIONS IN CANADA	68
STATISTICS CANADA	68
RX&D, CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES	68
CGPA (CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION)	68
NDMAC (THE NONPRESCRIPTION DRUG MANUFACTURERS ASSOCIATION OF CANADA)	69
COMPANY PROFILES: CANADA	69
ABBOTT LABORATORIES, LIMITED	69
ACTELION	69

ASTRAZENECA CANADA INC.	70
BAYER, INC.	70
BRISTOL-MYERS SQUIBB CANADA	71
ELI LILLY CANADA INC.	71
GLAXOSMITHKLINE INC.	72
HOFFMANN-LA ROCHE LIMITED	72
LUNDBECK CANADA INC.	73
MERCK FROSST CANADA LTD.	73
NOVARTIS PHARMACEUTICALS CANADA INC.	74
PFIZER CANADA INC.	74
PURDUE PHARMA (1956)	74
SANOFI-AVENTIS CANADA	75
SOLVAY PHARMA INC	75
WYETH PHARMACEUTICALS	75
Wyeth Pharmaceuticals (continued)	76
MEXICO	77
INTRODUCTION	77
TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	77
POPULATION AND DEMOGRAPHICS	77
TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)	77
THE MEXICAN HEALTHCARE SYSTEM	78
HEALTHCARE EXPENDITURE IN MEXICO	78
TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005	79
COMMON HEALTH PROBLEMS IN MEXICO	79
OBESITY AND RELATED CONDITIONS	79
DIABETES: THE LEADING CAUSE OF DEATH	79
HIV INFECTION	80
PHARMACEUTICAL REGULATION AND PRICING	80
MARKET SECTORS	81
BRANDED PRESCRIPTION PHARMACEUTICALS	81
TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	82
GENERIC DRUGS	82
TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	83
OVER-THE-COUNTER (OTC) MEDICATIONS IN MEXICO	83
TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	83
IMPORTANT ORGANIZATIONS IN MEXICO	84
STATISTICS MEXICO: SISTEMAS NACIONALES ESTADÍSTICO Y DE INFORMACIÓN GEOGRÁFICA (SNEIG)	84
AFAMELA (ASOCIACION DE FABRICANTES DE MEDICAMENTOS DE LIBRE ACCESO AC)	84

AMIIF (ASOCIACIÓN MEXICANA DE INDUSTRIALES DE INVESTIGACIÓN FARMACÉUTICA A.C., MEXICAN ASSOCIATION OF PHARMACEUTICAL COMPANIES)	84
CANIFARMA (CAMARA NACIONAL DE LA INDUSTRIA FARMACEUTICA)	85
FIFARMA, THE LATIN AMERICAN FEDERATION OF THE PHARMACEUTICAL INDUSTRY	85
ILAR (INDUSTRIO LATINOAMERICANA DE AUTOMEDICACION RESPONSABLE)	85
BRAZIL	86
INTRODUCTION	86
TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	86
POPULATION AND DEMOGRAPHICS	86
TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)	87
HEALTHCARE AND HEALTH PROBLEMS IN BRAZIL	87
THE HEALTHCARE SYSTEM (MEDICARE)	87
PHARMACEUTICAL PRICING	87
HEALTH PROBLEMS IN BRAZIL	88
MARKET SECTORS	89
BRANDED PRESCRIPTION PHARMACEUTICALS	89
TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	90
GENERIC DRUGS	90
TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	90
OVER-THE-COUNTER MEDICATIONS	90
TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ MILLIONS)	91
IMPORTANT ORGANIZATIONS IN BRAZIL	91
BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS	91
EUROPE	92
HEALTHCARE IN EUROPE	92
REIMBURSEMENT OF PHARMACEUTICALS	93
POPULATION DEMOGRAPHICS IN EUROPE	93
POPULATION GROWTH, MEDIAN AGE, AND LIFE EXPECTANCY	93
EXCESS WEIGHT	94
LIFE EXPECTANCY IN EUROPE	95
PHARMACEUTICAL MARKETS IN EUROPE	96
TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 (\$ BILLIONS)	96
PROPRIETARY PRESCRIPTION MEDICATIONS (ALSO CALLED BRANDED MEDICATIONS AND ETHICAL PHARMACEUTICALS)	97
TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	97
DATA EXCLUSIVITY	98

GENERIC MEDICATIONS	98
TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	99
GENERIC SMALL MOLECULES	99
BIOSIMILARS	99
OVER-THE-COUNTER MEDICATIONS	100
TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	100
FRANCE	101
INTRODUCTION	101
TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	101
DRIVERS OF PHARMACEUTICAL SALES GROWTH	102
POPULATION AND DEMOGRAPHICS	102
TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)	102
FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)	103
TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)	104
HEALTHCARE EXPENDITURE IN FRANCE	104
TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005	104
COMMON HEALTH PROBLEMS IN FRANCE	105
ALZHEIMER'S DISEASE AND RELATED DEMENTIAS	105
TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)	105
OBESITY AND RELATED CONDITIONS	105
DIABETES	106
CARDIOVASCULAR DISEASE	106
TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)	107
PHARMACEUTICAL PRICING	108
FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%)	109
FIGURE 7 (CONTINUED)	110
MARKET SECTORS	110
BRANDED PRESCRIPTION PHARMACEUTICALS	110
TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	110
GENERIC DRUGS	111
TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	111
FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE)	112
DRIVERS AND RESTRAINTS	113
OVER-THE-COUNTER (OTC) MEDICATIONS IN FRANCE	113
TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	114

TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)	114
EXPORT-IMPORT PROFILE	115
TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (\$ BILLIONS)	115
TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (\$ BILLIONS)	116
PHARMACEUTICAL DISTRIBUTION	116
WHOLESALEERS	116
FIGURE 9 LEADING WHOLESALEERS MARKET SHARE, FRANCE, 2006-2007 (% SHARE)	117
FRANCE'S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS	118
TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)	118
TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)	118
IMPORTANT ORGANIZATIONS IN FRANCE	118
INSEE (NATIONAL INSTITUTE FOR STATISTICS AND ECONOMIC STUDIES)	118
LEEM, THE FRENCH PHARMACEUTICAL COMPANIES ASSOCIATION	119
CSRP (SYNDICATE OF PHARMACEUTICAL DISTRIBUTORS):	119
FRANCE ALZHEIMER:	119
COMPANY PROFILES: FRANCE	119
BIOGARAN	119
CERP	120
MERCK GENERIQUES	120
SANDOZ: (SEE GERMANY)	120
SANOFI-AVENTIS	120
Sanofi-Aventis (Continued)	121
GERMANY	122
INTRODUCTION	122
TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	122
POPULATION AND DEMOGRAPHICS	122
TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)	123
TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)	123
FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)	124
THE GERMAN HEALTHCARE SYSTEM	124
HEALTHCARE EXPENDITURE IN GERMANY	125
TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005	125
COMMON HEALTH PROBLEMS IN GERMANY	126
ALZHEIMER'S DISEASE AND RELATED DEMENTIAS	126
TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)	126
OBESITY AND RELATED CONDITIONS	126

DIABETES	127
CARDIOVASCULAR DISEASE	127
TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)	128
PRICING AND REIMBURSEMENT OF PHARMACEUTICAL AGENTS	129
FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%)	130
FIGURE 11 (CONTINUED)	131
MARKET SECTORS	131
BRANDED PRESCRIPTION PHARMACEUTICALS	131
TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	131
GENERIC DRUGS	132
TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	132
DRIVERS AND RESTRAINTS	132
OVER-THE-COUNTER MEDICATIONS	133
TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	134
TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)	134
PHARMACEUTICAL DISTRIBUTION	134
WHOLESALERS	134
FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006–2007 (% SHARE)	135
GERMAN PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS	136
TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)	136
TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)	136
IMPORTANT ORGANIZATIONS IN GERMANY	137
DESTATIS (FEDERAL STATISTICAL OFFICE)	137
GERMAN FEDERAL MINISTRY FOR EDUCATION AND RESEARCH	137
DEUTSCHE DIABETES-UNION	137
PHARMA PRIVAT	137
BAH, BUNDESVERBAND DER ARZNEIMITTEL-HERSTELLER E.V.	137
VFA, THE GERMAN ASSOCIATION OF RESEARCH-BASED PHARMACEUTICAL COMPANIES	138
COMPANY PROFILES: GERMANY	138
CELESIO AG	138
MERCK KGAA	139
SANDOZ	140
STADA ARZNEIMITTEL AG	140
UNITED KINGDOM (U.K.)	141
INTRODUCTION	141
TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	141

DRIVERS OF PHARMACEUTICAL SALES GROWTH	142
POPULATION AND DEMOGRAPHICS	142
TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)	142
FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)	143
TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)	144
THE U.K. HEALTHCARE SYSTEM	144
HEALTHCARE EXPENDITURE IN THE U.K.	144
TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005	145
COMMON HEALTH PROBLEMS IN THE U.K.	145
ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS	145
TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)	145
OBESITY AND RELATED CONDITIONS	146
DIABETES	146
CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)	147
TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)	147
TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 (\$ MILLIONS)	148
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN THE U.K. AND REVENUE BREAKDOWN	148
MARKET SECTORS	149
BRANDED PRESCRIPTION PHARMACEUTICALS	149
TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	150
TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)	150
GENERIC DRUGS	151
TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	151
DRIVERS AND RESTRAINTS	152
OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.K.	152
TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	152
TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)	153
EXPORT-IMPORT PROFILE	153
TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 (\$ BILLIONS)	154
PHARMACEUTICAL DISTRIBUTION	154
WHOLESALE	154
TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF TOTAL MARKET)	154
U.K.'S PHARMACEUTICAL EXPORTS AND IMPORTS IN POUNDS STERLING	155

TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)	155
IMPORTANT ORGANIZATIONS IN THE U.K.	155
NATIONAL STATISTICS U.K.	155
ABPI, THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY	155
THE BRITISH ASSOCIATION OF PHARMACEUTICAL WHOLESALERS (BAPW)	156
COMPANY PROFILES: U.K.	156
AAH PHARMACEUTICALS	156
GLAXOSMITHKLINE (GSK)	156
MAWDSLEY-BROOKS & CO. LTD.	157
PHOENIX HEALTHCARE DISTRIBUTION, LTD.	158
UNICHEM	158
Unichem (Continued)	159
ITALY	160
INTRODUCTION	160
TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	160
DRIVERS OF PHARMACEUTICAL SALES GROWTH	161
POPULATION AND DEMOGRAPHICS	161
TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)	161
FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)	162
TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)	162
THE ITALIAN HEALTHCARE SYSTEM AND GROWTH DRIVERS	163
TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005	163
COMMON HEALTH PROBLEMS IN ITALY	164
ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS	164
OBESITY AND RELATED CONDITIONS	164
DIABETES	164
CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)	165
TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)	165
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN ITALY	165
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN ITALY	166
FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%)	166
FIGURE 15 (CONTINUED)	167
MARKET SECTORS	167
BRANDED PRESCRIPTION PHARMACEUTICALS	167
TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	167
GENERIC DRUGS	168
TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	168

DRIVERS AND RESTRAINTS	168
OVER-THE-COUNTER MEDICATIONS	169
TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	169
TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)	170
EXPORT-IMPORT PROFILE	170
TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (\$ BILLIONS, ROUNDED)	170
TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)	171
TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (\$ BILLIONS)	172
TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)	172
ITALY'S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS	172
TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)	173
TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)	173
IMPORTANT ORGANIZATIONS IN ITALY	173
NATIONAL INSTITUTE FOR STATISTICS (ISTITUTO NAZIONALE DI STATISTICA)	173
FARMINDUSTRIA, THE PHARMACEUTICAL MANUFACTURER'S ASSOCIATION OF ITALY	174
ASSOGENERICI, THE ITALIAN NATIONAL ASSOCIATION OF GENERIC PHARMACEUTICALS	174
SPAIN	175
INTRODUCTION	175
TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	175
DRIVERS OF PHARMACEUTICAL SALES GROWTH	176
POPULATION AND DEMOGRAPHICS	176
TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)	176
FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)	177
TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)	177
THE SPANISH HEALTHCARE SYSTEM, PRICING, AND PHARMACEUTICAL GROWTH DRIVERS	178
THE HEALTHCARE SYSTEM	178
TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005	178
DRUG PRICING POLICIES	179
COMMON HEALTH PROBLEMS IN SPAIN	179
ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS	179
OBESITY AND RELATED CONDITIONS	180
DIABETES	180

CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)	
180	
TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006	181
GROWTH DRIVERS	181
BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN SPAIN	181
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN SPAIN	182
FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%)	182
FIGURE 17 (CONTINUED)	183
MARKET SECTORS	183
BRANDED PRESCRIPTION PHARMACEUTICALS	183
TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	183
GENERIC DRUGS	184
TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	184
DRIVERS AND RESTRAINTS	184
OVER-THE-COUNTER MEDICATIONS	185
TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ MILLIONS)	185
EXPORT-IMPORT PROFILE	186
TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)	186
TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)	187
IMPORTANT ORGANIZATIONS IN SPAIN	187
NATIONAL STATISTICS INSTITUTE (INSTITUTO NACIONAL DE ESTADISTICA)	187
FARMAINDUSTRIA, THE NATIONAL ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY IN SPAIN	187
AESG, THE SPANISH ASSOCIATION OF GENERIC PHARMACEUTICALS MANUFACTURERS	188
ANEPF, THE NATIONALS ASSOCIATION OF OVER-THE-COUNTER MEDICATIONS	188
CEAFA, CONFEDERATION ESPANOLA DE FAMILIARES ENFERMOS DE ALZHEIMER'S Y OTRAS DEMENCIAS	188
SMALLER PHARMACEUTICAL MARKETS IN EUROPE	189
GREECE	189
INTRODUCTION	189
TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	189
POPULATION AND DEMOGRAPHICS	189
TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)	190
FIGURE 18 GREECE: POPULATION, 1998-2013 (MILLIONS)	190

TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)	
191	
THE GREEK HEALTHCARE SYSTEM	191
Structure of the Healthcare System	191
Healthcare Expenditures	191
TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005	192
COMMON HEALTH PROBLEMS IN GREECE	192
Pharmaceutical Pricing	193
TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004	193
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN GREECE	
194	
FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%)	
194	
Growth Drivers	194
Barriers to Pharmaceutical Revenue Growth in Greece	195
MARKET SECTORS	195
Branded Prescription Pharmaceuticals	195
TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	195
Generic Drugs	196
TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	196
Drivers and Restraints	196
Over-the-Counter Medications	196
TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ MILLIONS)	197
TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)	197
IMPORTANT ORGANIZATIONS IN GREECE	197
STATISTICS GREECE	197
THE HELLENIC ASSOCIATION OF PHARMACEUTICAL COMPANIES (SFEE)	
198	
EFEX, THE GREEK PROPRIETARY ASSOCIATION	198
THE NETHERLANDS	198
INTRODUCTION	198
TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	199
POPULATION AND DEMOGRAPHICS	199
TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)	200
FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)	200
TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)	201
THE DUTCH HEALTHCARE SYSTEM	201
Structure of the Healthcare System	201

Healthcare Expenditures	202
TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005	202
COMMON HEALTH PROBLEMS IN THE NETHERLANDS	202
Drug Pricing	203
REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN THE NETHERLANDS	203
FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%)	204
MARKET SECTORS	204
Branded Prescription Pharmaceuticals	204
TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	205
Generic Drugs	205
TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	206
Drivers and Restraints	206
Over-the-Counter Medications	206
TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ MILLIONS)	207
TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)	207
IMPORTANT ORGANIZATIONS IN THE NETHERLANDS	208
STATISTICS NETHERLANDS	208
NEFARMA, THE ASSOCIATION OF INNOVATE PHARMACEUTICALS IN THE NETHERLANDS	208
BOGIN, THE ASSOCIATION OF DUTCH GENERIC MEDICATIONS INDUSTRY	208
NEPROPHARM, THE NETHERLANDS ASSOCIATION OF OVER-THE-COUNTER PRODUCTS	208
BELGIUM	209
INTRODUCTION	209
TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	209
POPULATION AND DEMOGRAPHICS	209
TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)	210
FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)	210
TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)	211
THE BELGIAN HEALTHCARE SYSTEM	211
Structure of the Healthcare System	211
TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005	212
COMMON HEALTH PROBLEMS IN BELGIUM	212
DRUG PRICING	213

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN BELGIUM	
213	
FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%)	214
MARKET SECTORS	214
Branded Prescription Pharmaceuticals	214
TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	215
Generic Drugs	215
TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	215
Over-the-Counter Medications	216
TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ MILLIONS)	217
TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)	217
IMPORTANT ORGANIZATIONS IN BELGIUM	217
STATISTICS BELGIUM	217
PHARMA.BE, THE GENERAL ASSOCIATION OF THE MEDICINES INDUSTRY	218
EUROGENERICS	218
POLAND	218
INTRODUCTION	218
TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	219
POPULATION AND DEMOGRAPHICS	219
TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)	219
FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)	220
TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)	220
COMMON HEALTH PROBLEMS IN POLAND	221
THE POLISH HEALTHCARE SYSTEM	221
Structure of the Healthcare System	221
TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005	222
DRUG PRICING	222
MARKET SECTORS	223
Branded Prescription Pharmaceuticals	223
TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	223
Generic Drugs	224
TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	224
Over-the-Counter Medications	224
TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ MILLIONS)	225

TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)	225
IMPORTANT ORGANIZATIONS IN POLAND	226
POLISH CENTRAL STATISTICS OFFICE	226
POLFARMED, POLISH CHAMBER OF PHARMACEUTICALS INDUSTRY AND MEDICAL DEVICES	226
PASMI, THE POLISH ASSOCIATION OF THE SELF-MEDICATION INDUSTRY	226
PORTUGAL	226
INTRODUCTION	226
TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	227
POPULATION AND DEMOGRAPHICS	227
TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)	227
FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)	228
TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)	228
THE PORTUGUESE HEALTHCARE SYSTEM	229
Structure of the Healthcare System	229
TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005	229
Pharmaceutical Pricing	229
FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%)	230
FIGURE 26 (CONTINUED)	231
COMMON HEALTH PROBLEMS IN PORTUGAL	231
MARKET SECTORS	232
Branded Prescription Pharmaceuticals	232
TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	232
Generic Drugs	232
TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	233
Over-the-Counter Medications	233
TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ MILLIONS)	234
TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)	234
IMPORTANT ORGANIZATIONS IN PORTUGAL	234
STATISTICS PORTUGAL	234
APOGEN, PORTUGUESE ASSOCIATION OF GENERIC MEDICATIONS	235
APIFARMA, THE ASSOCIATION OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY	235
SWITZERLAND	235
INTRODUCTION	235

TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	236
POPULATION AND DEMOGRAPHICS	236
TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)	236
FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)	237
TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)	237
Common Health Problems in Switzerland	238
THE SWISS HEALTHCARE SYSTEM	238
Structure of the Healthcare System	238
TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005	239
Pharmaceutical Environment and Pricing	239
Pharmaceutical Environment ... (Continued)	240
FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%)	241
MARKET SECTORS	241
Branded Prescription Pharmaceuticals	241
TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	242
Generic Drugs	242
TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	243
Over-the-Counter Medications	243
TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ MILLIONS)	243
TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)	244
IMPORTANT ORGANIZATIONS IN SWITZERLAND	244
SWISS FEDERAL STATISTICS OFFICE	244
COMPANY PROFILES	245
NOVARTIS INTERNATIONAL AG	245
SWEDEN	246
INTRODUCTION	246
TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$ BILLIONS)	246
POPULATION AND DEMOGRAPHICS	246
TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)	247
FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)	247
TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)	248
HEALTH PROBLEMS AND HEALTHCARE IN SWEDEN	248
The Healthcare System	248
TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005	248
Pharmaceutical Pricing	249

FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)
250

Health Problems in Sweden 251

TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF
TOTAL MARKET, BY VALUE) 251

MARKET SECTORS 252

Branded Pharmaceuticals 252

TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH
2013 (\$ BILLIONS) 252

Generic Drugs 252

TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH
2013 (\$ BILLIONS) 253

Over-the-Counter Medications 253

TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$
MILLIONS) 253

IMPORTANT ORGANIZATIONS IN SWEDEN 254

STATISTICS SWEDEN 254

FGL, THE SWEDISH ASSOCIATION FOR GENERIC PHARMACEUTICALS 254

AUSTRIA 254

INTRODUCTION 254

TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH
2013 (\$ BILLIONS) 255

POPULATION AND DEMOGRAPHICS 255

TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
255

FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS) 256

TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)
256

HEALTHCARE AND HEALTH PROBLEMS IN AUSTRIA 257

The Healthcare System 257

Pharmaceutical Pricing 257

TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005 258

Health Problems in Austria 258

MARKET SECTORS 259

Branded Prescription Pharmaceuticals 259

TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH
2013 (\$ BILLIONS) 259

Generic Drugs 259

TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH
2013 (\$ BILLIONS) 260

Over-the-Counter Medications 260

TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 (\$
MILLIONS) 260

IMPORTANT ORGANIZATIONS IN AUSTRIA 260

STATISTICS AUSTRIA 260

PHARMIG, THE 261

IGEPHA, THE AUSTRIAN SELF-MEDICATION INDUSTRY	261
HUNGARY	261
INTRODUCTION	261
TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	262
POPULATION AND DEMOGRAPHICS	262
HEALTH PROBLEMS AND HEALTHCARE IN HUNGARY	262
The Healthcare System	262
Pharmaceutical Pricing	263
Health Problems in Hungary	263
MARKET SECTORS	264
Branded Prescription Pharmaceuticals	264
TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	265
Generic Drugs	265
TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	266
Over-the-Counter Medications	266
TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ MILLIONS)	266
IMPORTANT ORGANIZATIONS IN HUNGARY	267
HUNGARIAN CENTRAL STATISTICS OFFICE	267
MAGYOSZ, THE HUNGARIAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION	267
FINLAND	267
INTRODUCTION	267
TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	268
POPULATION AND DEMOGRAPHICS	268
TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)	268
TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)	269
HEALTH PROBLEMS AND HEALTHCARE IN FINLAND	269
The Healthcare System	269
PHARMACEUTICAL PRICING	269
Health Problems in Finland	270
MARKET SECTORS	271
TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)	271
Branded Prescription Pharmaceuticals	272
TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	272
Generic Drugs	273
TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	273

Over-the-Counter Medications	273
TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ MILLIONS)	273
IMPORTANT ORGANIZATIONS IN FINLAND	274
STATISTICS FINLAND	274
IMPORTANT ORGANIZATIONS IN EUROPE	274
THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA)	274
THE EUROPEAN GENERICS ASSOCIATION (EGA)	275
THE ASSOCIATION OF THE EUROPEAN SELF-MEDICATION INDUSTRY (AESGP)	275
ASIA	276
JAPAN	276
INTRODUCTION	276
TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	276
POPULATION AND DEMOGRAPHICS	276
TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)	277
TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)	277
FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)	278
THE JAPANESE HEALTHCARE SYSTEM	278
Healthcare Expenditures in Japan	279
TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005	279
Common Health Problems in Japan	280
TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005	280
Cancer	280
TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005	281
Alzheimer's Disease and Related Dementias	281
Obesity and Diabetes	281
Cardiovascular Disease	282
Smoking	282
PHARMACEUTICAL PRICING	282
Pharmaceutical Pricing (Continued)	283
Pricing of Generic Drugs	284
MARKET SECTORS	285
Branded Prescription Pharmaceuticals	285
TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	286
Generic Drugs	286
TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	286
OVER-THE-COUNTER MEDICATIONS IN JAPAN	287
TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	287
TABLE 203 LEADING OTC CATEGORIES, JAPAN	287

IMPORTANT ORGANIZATIONS IN JAPAN	288
STATISTICS BUREAU	288
MINISTRY OF HEALTH, LABOUR, & WELFARE	288
JPMA, JAPAN PHARMACEUTICAL MANUFACTURER'S ASSOCIATION	288
JSMI, JAPANESE SELF-MEDICATION INDUSTRY	288
COMPANY PROFILES	289
ASTELLAS PHARMA	289
SAWAI PHARMACEUTICAL COMPANY LTD.	289
TAKEDA PHARMACEUTICAL COMPANY LTD.	289
CHINA	290
INTRODUCTION	290
TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ BILLIONS)	290
POPULATION AND DEMOGRAPHICS	291
TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)	291
TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)	292
HEALTHCARE AND HEALTH PROBLEMS IN CHINA	292
The Healthcare System	292
Pharmaceutical Pricing	293
Health Problems in China	294
MARKET SECTORS	295
Branded Prescription Pharmaceuticals	295
TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ BILLIONS)	296
Generic Drugs	296
Over-the-Counter Medications	297
TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ MILLIONS)	297
IMPORTANT ORGANIZATIONS IN CHINA	297
NATIONAL BUREAU OF STATISTICS OF CHINA	297
SOUTH KOREA	298
INTRODUCTION	298
TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ BILLIONS)	298
POPULATION AND DEMOGRAPHICS	298
TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)	299
TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)	299
HEALTHCARE AND HEALTH PROBLEMS IN SOUTH KOREA	300
The Healthcare System	300
Pharmaceutical Pricing	300
Health Problems in South Korea	301
TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003	302
MARKET SECTORS	303

Branded and Generic Prescription Pharmaceuticals	303
TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ BILLIONS)	303
Over-the-Counter Medications	304
TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ MILLIONS)	304
IMPORTANT ORGANIZATIONS IN SOUTH KOREA	304
KOREAN NATIONAL STATISTICAL OFFICE	304
AUSTRALIA	305
INTRODUCTION	305
TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	305
POPULATION AND DEMOGRAPHICS	305
TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)	306
HEALTHCARE AND HEALTH PROBLEMS IN AUSTRALIA	306
The Healthcare System (Medicare)	306
Pharmaceutical Pricing	307
Health Problems in Australia	308
TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)	308
TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)	309
TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)	310
MARKET SECTORS	310
Branded Prescription Pharmaceuticals	310
TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	311
Generic Drugs	311
TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	311
Over-the-Counter Medications	312
TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ MILLIONS)	312
TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)	313
IMPORTANT ORGANIZATIONS IN AUSTRALIA	313
AUSTRALIAN BUREAU OF STATISTICS	313
DEPARTMENT OF INNOVATION, INDUSTRY, SCIENCE, AND RESEARCH	313
MEDICINES AUSTRALIA	313
INDIA	314
INTRODUCTION	314
TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	314

POPULATION AND DEMOGRAPHICS	314
TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)	315
HEALTHCARE AND HEALTH PROBLEMS IN INDIA	315
Pharmaceutical Pricing	315
HEALTH PROBLEMS IN INDIA	316
MARKET SECTORS	317
Overview	317
TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 (\$ MILLIONS)	317
Barriers to Growth in India	318
Branded Prescription Pharmaceuticals	318
TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	319
Generics	319
Over-the-Counter Medications	320
TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	320
IMPORTANT ORGANIZATIONS IN INDIA	321
MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION	321
MINISTRY OF HEALTH	321
IDMA, THE INDIAN DRUG MANUFACTURERS ASSOCIATION	321
OPPI, THE ORGANISATION OF PHARMACEUTICAL PRODUCERS OF INDIA	321
COMPANY PROFILES	322
RANBAXY LABORATORIES, LTD	322
CIPLA LTD.	323
DR. REDDY'S LABORATORIES LTD.	323
SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE	324
PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES NOT COVERED IN DETAIL IN THIS REPORT	325
PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES ...	325
PHARMACEUTICAL MARKETS...(CONTINUED)	326
SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE	327
SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 (\$ BILLIONS)	LI
TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)	4
TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 (\$ BILLIONS)	5
TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 (\$ BILLIONS)	6

TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	7
TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	7
TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	8
TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 (\$ BILLIONS, % OF TOTAL)	8
TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	9
TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)	10
TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)	11
TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006	13
TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 (\$ BILLIONS, %)	14
TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 (\$ BILLIONS)	15
TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)	15
TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)	18
TABLE 16 INVASIVE CANCER, U.S., 2004 (%)	19
TABLE 17 CANCER DEATHS, U.S., 2004 (%)	20
TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)	21
TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007	30
TABLE 20 NME APPROVALS BY DISORDER, 2004–MARCH 20, 2008	33
TABLE 21 BOTOX SALES, 1993-2012 (\$ MILLIONS)	34
TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)	38
TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (% , \$ BILLIONS)	41
TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)	41
TABLE 25 EXPORT–IMPORT PROFILE, U.S., 1995–2006 (\$ BILLIONS)	42
TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	43
TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 (\$ BILLIONS)	44
TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	45
TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 (\$ BILLIONS)	46
TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	59
TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)	60

TABLE 32	DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)	
		61
TABLE 33	HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005	62
TABLE 34	BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	65
TABLE 35	GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	66
TABLE 36	OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 (\$ BILLIONS)	67
TABLE 37	TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)	67
TABLE 38	OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	77
TABLE 39	POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)	77
TABLE 40	HEALTHCARE EXPENDITURE: MEXICO, 2000-2005	79
TABLE 41	BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	82
TABLE 42	GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	83
TABLE 43	OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 (\$ BILLIONS)	83
TABLE 44	OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	86
TABLE 45	POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)	87
TABLE 46	BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	90
TABLE 47	GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ BILLIONS)	90
TABLE 48	OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 (\$ MILLIONS)	91
TABLE 49	TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 (\$ BILLIONS)	96
TABLE 50	BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	97
TABLE 51	GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	99
TABLE 52	OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 (\$ BILLIONS)	100
TABLE 53	OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	101
TABLE 54	POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)	102
TABLE 55	DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)	104
TABLE 56	HEALTHCARE EXPENDITURE: FRANCE, 2000-2005	104

TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)	105
TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)	107
TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	110
TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	111
TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 (\$ BILLIONS)	114
TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)	114
TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (\$ BILLIONS)	115
TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (\$ BILLIONS)	116
TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)	118
TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)	118
TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	122
TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)	123
TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)	123
TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005	125
TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)	126
TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)	128
TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	131
TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	132
TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 (\$ BILLIONS)	134
TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)	134
TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)	136
TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)	136
TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	141
TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)	142
TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)	144
TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005	145

TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)	145
TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)	147
TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 (\$ MILLIONS)	148
TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	150
TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)	150
TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	151
TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 (\$ BILLIONS)	152
TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)	153
TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 (\$ BILLIONS)	154
TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF TOTAL MARKET)	154
TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)	155
TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	160
TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)	161
TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)	162
TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005	163
TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)	165
TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	167
TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	168
TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 (\$ BILLIONS)	169
TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)	170
TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (\$ BILLIONS, ROUNDED)	170
TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)	171
TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (\$ BILLIONS)	172
TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)	172

TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)	173
TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)	173
TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	175
TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)	176
TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)	177
TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005	178
TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006	181
TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	183
TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ BILLIONS)	184
TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 (\$ MILLIONS)	185
TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)	186
TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)	187
TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	189
TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)	190
TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)	191
TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005	192
TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004	193
TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	195
TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ BILLIONS)	196
TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 (\$ MILLIONS)	197
TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)	197
TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	199
TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)	200
TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)	201
TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005	202

TABLE 132	BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	205
TABLE 133	GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ BILLIONS)	206
TABLE 134	OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 (\$ MILLIONS)	207
TABLE 135	LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)	207
TABLE 136	OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	209
TABLE 137	POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)	210
TABLE 138	DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)	211
TABLE 139	HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005	212
TABLE 140	BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	215
TABLE 141	GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ BILLIONS)	215
TABLE 142	OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 (\$ MILLIONS)	217
TABLE 143	LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)	217
TABLE 144	OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	219
TABLE 145	POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)	219
TABLE 146	DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)	220
TABLE 147	HEALTHCARE EXPENDITURE: POLAND, 2000-2005	222
TABLE 148	BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	223
TABLE 149	GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ BILLIONS)	224
TABLE 150	OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 (\$ MILLIONS)	225
TABLE 151	LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)	225
TABLE 152	OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	227
TABLE 153	POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)	227
TABLE 154	DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)	228
TABLE 155	HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005	229

TABLE 156	BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	232
TABLE 157	GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ BILLIONS)	233
TABLE 158	OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 (\$ MILLIONS)	234
TABLE 159	LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)	234
TABLE 160	OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	236
TABLE 161	POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)	236
TABLE 162	DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)	237
TABLE 163	HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005	239
TABLE 164	BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	242
TABLE 165	GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ BILLIONS)	243
TABLE 166	OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 (\$ MILLIONS)	243
TABLE 167	LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)	244
TABLE 168	OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$ BILLIONS)	246
TABLE 169	POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)	247
TABLE 170	DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)	248
TABLE 171	HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005	248
TABLE 172	LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF TOTAL MARKET, BY VALUE)	251
TABLE 173	BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$ BILLIONS)	252
TABLE 174	GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$ BILLIONS)	253
TABLE 175	OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 (\$ MILLIONS)	253
TABLE 176	OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 (\$ BILLIONS)	255
TABLE 177	POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)	255
TABLE 178	DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)	256
TABLE 179	HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005	258

TABLE 180	BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 (\$ BILLIONS)	259
TABLE 181	GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 (\$ BILLIONS)	260
TABLE 182	OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 (\$ MILLIONS)	260
TABLE 183	OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	262
TABLE 184	BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	265
TABLE 185	GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ BILLIONS)	266
TABLE 186	OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 (\$ MILLIONS)	266
TABLE 187	OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	268
TABLE 188	POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)	268
TABLE 189	DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)	269
TABLE 190	LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)	271
TABLE 191	BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	272
TABLE 192	GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ BILLIONS)	273
TABLE 193	OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 (\$ MILLIONS)	273
TABLE 194	OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	276
TABLE 195	POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)	277
TABLE 196	DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)	277
TABLE 197	HEALTHCARE EXPENDITURE: JAPAN, 2000-2005	279
TABLE 198	LEADING CAUSES OF DEATH, JAPAN, 2005	280
TABLE 199	LEADING FORMS OF CANCER, JAPAN, 2005	281
TABLE 120	BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	286
TABLE 201	GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	286
TABLE 202	OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 (\$ BILLIONS)	287
TABLE 203	LEADING OTC CATEGORIES, JAPAN	287
TABLE 204	OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ BILLIONS)	290
TABLE 205	POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)	291

TABLE 206	DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)	292
TABLE 207	PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ BILLIONS)	296
TABLE 208	OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 (\$ MILLIONS)	297
TABLE 209	OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ BILLIONS)	298
TABLE 210	POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)	299
TABLE 211	DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)	299
TABLE 212	LEADING CAUSES OF DEATH, SOUTH KOREA, 2003	302
TABLE 213	PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ BILLIONS)	303
TABLE 214	OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 (\$ MILLIONS)	304
TABLE 215	OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	305
TABLE 216	POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)	306
TABLE 217	LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)	308
TABLE 218	LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)	309
TABLE 219	COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)	310
TABLE 220	BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	311
TABLE 221	GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ BILLIONS)	311
TABLE 222	OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 (\$ MILLIONS)	312
TABLE 223	TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)	313
TABLE 224	OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	314
TABLE 225	POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)	315
TABLE 226	TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 (\$ MILLIONS)	317
TABLE 227	PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	319
TABLE 228	OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 (\$ BILLIONS)	320

SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS,
2006-2013 (\$ BILLIONS) LI

- FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS) 10
FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 (\$ BILLIONS) 12
FIGURE 3 NME APPROVALS, 1997-2007 28
FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007 29
FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS) 60
FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS) 103
FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%) 109
FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE) 112
FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006–2007 (% SHARE) 117
FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS) 124
FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%) 130
FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006–2007 (% SHARE) 135
FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS) 143
FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS) 162
FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%) 166
FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS) 177
FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%) 182
FIGURE 18 GREECE: POPULATION, 1998-2013 (MILLIONS) 190
FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%) 194
FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS) 200
FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%) 204
FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS) 210
FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%) 214
FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS) 220
FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS) 228
FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%) 230
FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS) 237
FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%) 241
FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS) 247

FIGURE 30	VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)	
	250	
FIGURE 31	AUSTRIA: POPULATION, 1998-2013 (MILLIONS)	256
FIGURE 32	JAPAN: POPULATION, 1998-2013 (MILLIONS)	278